Walgreens discontinues negotiations; PBM Express Scripts shocked
ST. LOUIS — After Walgreens made its contract dispute with Express Scripts public on Tuesday morning, the pharmacy benefit manager stated it is open to continued negotiations with Walgreens.
"In these challenging economic times, it is critical that we all work together to keep medicines affordable and accessible," Express Scripts’ chairman and CEO George Paz said. "It is shocking to us that Walgreens would back away from the table with six months to go in the current agreement, especially considering that negotiations are part of the normal course of business."
In response to the news, Credit Suisse research analyst Ed Kelly said that the general consensus is that the issues will be settled.
“Walgreens is once again fighting to protect the longer-term profitability of its pharmacy business, similar to the dispute with CVS Caremark last year,” Kelly wrote in a research note released Wednesday morning. “We believe the company’s dispute with Express Scripts will be resolved shortly, as the lack of a deal would clearly harm both companies.”
If renewed negotiations don’t materialize, the parting of ways between Walgreens and Express Scripts would have an estimated 50 cents per share impact on Walgreens’ earnings, Kelly noted, and Express Scripts would be placed at a competitive disadvantage versus other PBMs without the almost 8,000 Walgreens and Duane Reade pharmacy locations in its network.
Credit Suisse maintained its “outperform” rating for Walgreens, suggesting that investors taking advantage of any volatility with stock prices now should reap the benefits by first quarter 2012 if Walgreens hits current earnings projections.
In its statement, Express Scripts challenged Walgreens’ assertion that the proposed reimbursement rates were below the published industry average cost to provide each prescription. “Over the next three years, the costs of nonspecialty branded medications are projected to increase approximately 10% per year [and] more than 30% over three years. The costs of branded specialty medications are projected to increase more than 14% per year [and] nearly 50% over three years, and more than $60 billion worth of branded medications will lose patent protection, opening the door to more affordable generic alternatives,” Paz stated.
However, the PBM is drawing its own line in the sand in preparing to continue on without Walgreens. “On average, another pharmacy within the Express Scripts network is within one-half mile of a Walgreens pharmacy. Even without Walgreens in our network, we meet all client guarantees for access.”
The practice of Pharmacy is really on the decline because of the fact that pharmacists are left out of the equation. Pharmacists currently are not in charge of their profession and that is a major problem. They are paid at a decent salary but are treated like cashiers in the stores. We are professionals and should be treated as such. The Walmarts of the world wouldn't have destroyed the profession if they were pharmacists. The leaders of the direction of the pharmacy practice are more concerned with their profits by negotiating away our respect among other professionals in health care. We should take back our profession.
Dr. Reddy’s brings generic Levaquin to market
HYDERABAD, India — Generic drug maker Dr. Reddy’s Labs has launched its version of a popular antibiotic.
The company said its levofloxacin tablets in the 250-mg, 500-mg and 750-mg strengths have entered the market, following the Food and Drug Administration’s approval of Dr. Reddy’s abbreviated new drug application. Dr. Reddy’s levofloxacin tablets in the 250-mg and 500-mg strengths are available in 50-count bottles, while the 750-mg strength bottle is available in 30-count bottles.
Levofloxacin tablets are a generic version of Levaquin, an Ortho-McNeil-Janssen Pharmaceuticals drug. The FDA earlier this week approved several generic versions of Levaquin in tablet, oral solution and injectable solution dosage forms.
U.S. sales of Levaquin totaled approximately $1.1 billion for the 12 months ended in March, according to IMS Health data.
No comments found
Endo completes acquisition of American Medical Systems
CHADDS FORD, Pa. — Endo Pharmaceuticals has acquired a provider of devices and therapies for male and female pelvic health.
Endo said its acquisition of American Medical Systems has boosted the drug maker’s devices and services business segment, and the combination of AMS with Endo’s existing platform will provide additional cost-effective solutions across the entire urology spectrum.
The company announced its definitive agreement to acquire AMS in a cash transaction valued for approximately $2.9 billion.
"Closing on this acquisition marks another milestone in the transformation of Endo and accelerates our strategy of building a diversified healthcare company, better able to respond to the changing economics that drive the U.S. healthcare environment," Endo president and CEO Dave Holveck said. "AMS accelerates our overall growth, and we are very excited about the potential of its current commercial portfolio, as well as potential new product introductions."
No comments found